Emerging Immunotargets in Metastatic Renal Cell Carcinoma Article

Full Text via DOI: 10.2174/1389450117666151209115753 PMID: 26648075 Web of Science: 000374119900004
International Collaboration

Cited authors

  • Kucharczyk, John; Matrana, Marc R.; Santoni, Matteo; Massari, Francesco; Scarpelli, Marina; Cheng, Liang; Lopez-Beltran, Antonio; Cascinu, Stefano; Montironi, Rodolfo; Holger, Moch


  • Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-alpha were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.

Publication date

  • 2016

Published in

International Standard Serial Number (ISSN)

  • 1389-4501

Start page

  • 771

End page

  • 776


  • 17


  • 7